Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02846571 · ClinicalTrials.gov registry record · Phase 1
Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye
A Phase 1 study of Diabetes, sponsored by Midhat H. Abdulreda.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 2
- Study locations
NCT02846571: Recruiting Phase 1 study of Diabetes, sponsored by Midhat H. Abdulreda.
NCT02846571 is a Phase 1 study of Diabetes that is actively recruiting participants, run by Midhat H. Abdulreda. The registered enrollment target is 2 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02846571, a Phase 1 study of Diabetes, is actively recruiting participants, sponsored by Midhat H. Abdulreda.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 2
- Study locations
Study Summary
The intervention in this trial is intraocular islet transplantation. A single dose of 1000 - 3000 Islet Equivalents (IEQ)/kg recipient body weight (BW) will be infused into the anterior chamber of the eye through a self-sealing incision in the peripheral cornea. The procedure is projected to take approximately 20-30 minutes. Transplant recipients in this study will receive localized maintenance immunosuppression via topical application of eye-drops.
Primary Outcome
Absence of, corneal decompensation, increased intraocular pressure (IOP), uveitis, cataract formation, retinal detachment, retinal bleeding, retinal vasculopathies, macular edema, optic neuropathy, and endophthalmitis in the transplanted eye
Conditions Studied
Interventions
- BIOLOGICAL Human Pancreatic Islet Transplantation
Study Locations (2)
Florida
- Bascom Palmer Eye Institute - Miami
- Diabetes Research Institute, University of Miami Miller School of Medicine - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-12-05 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What NCT02846571 shows while recruiting
NCT02846571 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Human Pancreatic Islet Transplantation is the first listed.
NCT02846571 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02846571 about?
NCT02846571 is a clinical study titled "Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye". The intervention in this trial is intraocular islet transplantation. A single dose of 1000 - 3000 Islet Equivalents (IEQ)/kg recipient body weight (BW) will be infused into the anterior chamber of the eye through a self-sealing incision in the peripheral cornea. The procedure is projected to take ap...
What is the current status of trial NCT02846571?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2019-12-05. Estimated completion is 2027-12-31.
What conditions does trial NCT02846571 study?
This clinical trial studies the following conditions: Diabetes.
What interventions are being tested in trial NCT02846571?
The interventions under investigation include: Human Pancreatic Islet Transplantation (BIOLOGICAL).
Who is sponsoring clinical trial NCT02846571?
This trial is sponsored by Midhat H. Abdulreda, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02846571 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02846571's enrollment target sits among peer trials
2 339th of 338 the lowest of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mitigating the Pro-inflammatory Phenotype of Obesity
RECRUITING · Phase 1
-
Insulin Balanced Infusion System
ACTIVE NOT RECRUITING · Phase 1
-
Ability of a Tea Leaf Extracts Preparation to Slow Down Carbohydrate and Fat Absorption
COMPLETED · Phase 1
-
Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections
COMPLETED · Phase 1
-
Family Management of Childhood Diabetes Study
COMPLETED · Phase 1
-
Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI